| Q99569141 | A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver |
| Q40290590 | A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria |
| Q36790155 | A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein |
| Q52350559 | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. |
| Q60914449 | A probabilistic model of pre-erythrocytic malaria vaccine combination in mice |
| Q53700367 | A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. |
| Q92965786 | Antibodies against Plasmodium falciparum malaria at the molecular level |
| Q44168441 | Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine |
| Q26314437 | Circumsporozoite protein as a potential target for antimalarials |
| Q64065218 | Comprehensive Review of Human -Specific CD8+ T Cell Epitopes |
| Q59387720 | Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin |
| Q92850206 | Design and assessment of TRAP-CSP fusion antigens as effective malaria vaccines |
| Q57606160 | Disordered epitopes as peptide vaccines |
| Q40259888 | Immune Responses in Malaria |
| Q58566399 | Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria |
| Q40129832 | Isolation and Characterization of Vaccine Candidate Genes Including CSP and MSP1 in Plasmodium yoelii |
| Q38735533 | Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. |
| Q56362064 | Malaria Vaccines: Recent Advances and New Horizons |
| Q58569727 | Malaria prevention: from immunological concepts to effective vaccines and protective antibodies |
| Q92976912 | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform |
| Q38558444 | Plasmodium Sporozoite Biology |
| Q48022505 | Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge |
| Q94662626 | Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein |
| Q40376689 | Recruited monocytes modulate malaria-induced lung injury through CD36-mediated clearance of sequestered infected erythrocytes. |
| Q36053524 | Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains |
| Q37696415 | Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes |
| Q41722577 | Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection. |
| Q92449403 | Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ) |
| Q90160111 | Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein |
| Q41349538 | T-dependent B cell responses to Plasmodium induce antibodies that form a high-avidity multivalent complex with the circumsporozoite protein. |
| Q89516787 | The Blood Stage Antigen RBP2-P1 of Plasmodium vivax Binds Reticulocytes and Is a Target of Naturally Acquired Immunity |
| Q60954894 | To B or Not to B: Understanding B Cell Responses in the Development of Malaria Infection |
| Q39170404 | Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection |
| Q64947790 | Vaccination With Sporozoites: Models and Correlates of Protection. |
| Q39296506 | Vaccines to Accelerate Malaria Elimination and Eventual Eradication |